This project has been flagged by a community member as inappropriate due to reason below.*
Slingshot & STAT have partnered to provide you with interviews with experts led by STAT's reporters. This call is on:

Discussing the Sickle Cell Landscape and Emerging Treatment Options Including Voxelotor, Rivipansel, and LentiGlobin.

Ticker(s): GBT, PFE, GLYC, BLUE

Who's the expert?

Name: Dr Cindy Neunert- MD

Institution: Columbia University

  • Pediatric Hematologist & Associate Professor of Pediatrics at Columbia University.
  • Currently treats 10-20 patients per week with sickle-cell disease in a practice with over 300 SCD patients.
  • Served as an investigator for the RESET clinical trial for SDC, and research interests are focused on understanding and evaluating patient-related outcomes and shared-decision making in benign hematology.   

Interview Goal
This conversation will be broken into three parts:
  • Understanding the Sickle Cell landscape, current treatment options, and unmet medical need
  • Reviewing the approvability case and commercial opportunity for voxelotor
  • Looking forward to treatment options in development currently including, Rivipansel and LentiGlobin

Are You Interested In These Questions?



7Days Left to Join Project
Call Date
Jul 23, 2019
Call Time
02:30 PM EDT
Wall Street Time

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.